| Biomarker ID | 391 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | Serum PSA + DRE + PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.092 (95% CI: 0–1.283) |
| Effect on Pathways | NA |
| Experiment | (Benign Samples + Gleason sums < 7) Vs ≥ 7 |
| Type of Biomarker | Diagnostic |
| Cohort | 86 patients were taken into consideration for the test. Benign + Gleason sum < 7 (n = 60) vs Gleason sum >7 (n = 14) |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.751 (95% CI: 0.638–0.864) |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | For Analysis, Serum PSA, plus Digital rectal Exam plus a marker was chosen for analysis and compared to whether they improved performance over analysis done by only Serum PSA + DRE |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PCA3 |